Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Mannkind Corporation clinical trials
The registry lists 66 studies whose lead sponsor is Mannkind Corporation or one of 1 company grouped under it. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 14, 2026.
Keep track of what changes. Save the Mannkind Corporation studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Mannkind Corporation.
- Mannkind Corporation57 studiesSame company
Something wrong?
- scPharmaceuticals, Inc.9 studies →Acquired — became part of Mannkind Corporation, Oct 7, 2025 · source ↗
Something wrong?
Focus areas
Conditions Mannkind Corporation leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 66. Browse all 66 →
- Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07679893Phase 2
- INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesRecruitingNCT07224321Phase 2
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy VolunteersRecruitingNCT06532942Phase 1
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT07344558Phase 1
- Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy VolunteersCompletedNCT06167707Phase 1
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionTerminatedNCT06418711Phase 3
- Afrezza® INHALE-1 Study in PediatricsCompletedNCT04974528Phase 3
- Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 DiabetesCompletedNCT05243628Phase 4
- INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 DiabetesCompletedNCT05904743Phase 4
- Afrezza® Dosing Optimization StudyCompletedNCT04849845Phase 4
- Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot StudyCompletedNCT04593823Phase 2
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart FailureCompletedNCT03458325Phase 3
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart FailureCompletedNCT02329834Phase 2/3
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Afrezza Safety and Pharmacokinetics Study in Pediatric PatientsCompletedNCT02527265Phase 2
- An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin TolerabilityCompletedNCT04161482Phase 1
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal VolunteersCompletedNCT03464864Phase 1
- Product Design Clinical Performance Study of sc2Wear Furosemide Combination ProductCompletedNCT02804282Phase 3
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral AdministrationCompletedNCT02350725Phase 1/2
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Pilot Study for First Clinical Use of sc2Wear Furosemide Combination ProductCompletedNCT02804035Phase 2
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone AdministrationCompletedNCT02561442Phase 2/3
Sponsor listed in the registry: scPharmaceuticals, Inc. · First submitted before scPharmaceuticals, Inc. became part of Mannkind Corporation
- Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary DiseaseTerminatedNCT00642616Phase 3
- Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes MellitusCompletedNCT02470637Phase 1
- PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)CompletedNCT02485327Phase 1
- Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation PowderNo longer availableNCT01798914
- Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 CartridgeCompletedNCT01902121Phase 1
- A 2-Month Safety Follow-Up TrialCompletedNCT00741429
- Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal ChallengeCompletedNCT00642681
- Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 InhalerTerminatedNCT01196104Phase 3
- Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate IntakeTerminatedNCT00747006Phase 2
- Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment PeriodCompletedNCT01445951Phase 3
- Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes MellitusCompletedNCT01451398Phase 3
- A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin LisproCompletedNCT00662857Phase 2
- Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-upCompletedNCT00309244Phase 3
- Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-WeeksTerminatedNCT00700622Phase 3
- An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' TrialCompletedNCT00754624Phase 2
- Efficacy & Safety of Inhaled Insulin in Type 1 DiabetesCompletedNCT00308308Phase 3
- A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 DiabetesCompletedNCT00570687Phase 2
- Safety of Inhaled Insulin With Type 1 and Type 2 DiabetesCompletedNCT00308737Phase 3
- Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 DiabetesCompletedNCT00332488Phase 3
- Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different SuppliersCompletedNCT01982604Phase 1
- A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)CompletedNCT00757367Phase 1
- A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01021891Phase 1
- Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney FunctionCompletedNCT00626249Phase 1
- Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 DiabetesCompletedNCT01544881Phase 1
- Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166TerminatedNCT01201928
- Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C InhalerCompletedNCT01490762Phase 1
- Vaccine Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00023647Phase 1
- Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human InsulinCompletedNCT00511979Phase 1
- Pharmacokinetic Study in Healthy VolunteersCompletedNCT01365117Phase 1
- A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes MellitusCompletedNCT00642538Phase 1